| Description |
1 online resource |
| Contents |
880-01 Front Cover; TRANSLATIONALIMMUNOTHERAPY OFBRAIN TUMORS; TRANSLATIONALIMMUNOTHERAPYOF BRAINTUMORS; Copyright; Contents; List of Contributors; Introduction to Translational Immunotherapy for Brain Tumors; TRANSLATIONAL IMMUNOTHERAPY FOR BRAIN TUMORS SUMMARY; PRIMER ON MALIGNANT GLIOMAS; THE POTENTIAL OF CANCER IMMUNOTHERAPY; CHALLENGES OF BRAIN TUMOR IMMUNOTHERAPY; CHAPTER OVERVIEW; References; I -- IIMMUNOLOGICALFEATURES OF BRAINTUMORS; 1 -- An Introduction to Immunotherapy in the Treatment of Brain Tumors; INTRODUCTION; THE IMMUNE RESPONSE; IMMUNE TOLERANCE |
|
880-01/(S Chemokine and Cytokine ApproachesDifferentiation; IL-4Rα Targeting; Arginase 1; Fibrinogen-Like Protein 2 Targeting; M1 Polarization or M2 Blockade; CLINICAL APPROACHES TO TARGETING MDSCS; References; 5 -- Tumor-Specific Mutations in Gliomas and Their Implications for Immunotherapy; INTRODUCTION; MUTATIONS AS IMMUNOTHERAPEUTIC TARGETS; ISOCITRATE DEHYDROGENASE 1 MUTATIONS IN GLIOMAS; IDH1 MUTATIONS AS AN IMMUNOTHERAPEUTIC TARGET; PRECLINICAL INVESTIGATIONS: IDH1-R132H PEPTIDE VACCINES; CLINICAL INVESTIGATIONS: IDH1-R132H PEPTIDE VACCINES |
|
UNIQUE ASPECTS OF THE CENTRAL NERVOUS SYSTEM IMMUNE RESPONSEThe Blood-Brain Barrier; The CNS Lymphatic System; Antigen Presentation in the CNS; CANCER IMMUNOTHERAPIES; References; 2 -- Immune Constitution of Patients With Brain Tumors; BACKGROUND AND DISCOVERY; CURRENT UNDERSTANDING: ANALYZING SYSTEMIC IMMUNE DYSFUNCTION; Lymphopenia; Lymphocyte Dysfunction; Regulatory T Cells; CURRENT UNDERSTANDING: ANALYZING THE TUMOR; Cytokine Dysregulation; Signal Transducer and Activator of Transcription-3; Indoleamine 2,3 Dioxygenase; CLINICAL OPPORTUNITIES |
|
Countering T Cell Dysfunction: Immune Checkpoint BlockadeCountering Regulatory T Cells and Lymphopenia; Countering Cytokine Dysregulation; Countering Tumor STAT3 and IDO Expression; CONCLUSION; References; 3 -- The Role of Regulatory T Cells and Indoleamine-2,3-dioxygenase in Brain Tumor Immunosuppression; BACKGROUND AND DISCOVERY; ORIGIN OF TREGS; FUNCTION OF TREGS; TREGS IN THE CANCER IMMUNITY CYCLE; TREGS AND GLIOMA; TRYPTOPHAN CATABOLISM IN IMMUNITY AND IN CANCER; IDO1, IDO2, AND TDO; THE AHR; MECHANISMS OF IMMUNE REGULATION BY THE IDO PATHWAY; THE IDO PATHWAY IN CANCER AND IN GLIOMA |
|
TARGETING TREGS IN PRECLINICAL MODELTARGETING IDO IN PRECLINICAL MODELS; CLINICAL TRIAL DATA; CONCLUSION; References; 4 -- The Role of Myeloid-Derived Suppressor Cells in Immunosuppression in Brain Tumors; BACKGROUND AND DISCOVERY OF THE MYELOID CELL; MDSCs in Mice; MDSCs in Humans; MDSC Activation, Proliferation, Migration, and Expansion; Suppressive Mechanisms Mediated by MDSCs; Suppression via Arg1 and iNOS; Suppression via Reactive Oxygen Species; Suppression via Peroxynitrite; Other Immunosuppressive Mechanisms; MDSCs in Glioma Development; PRECLINICAL DATA: TARGETING THE MDSC POPULATION |
| Notes |
Includes index |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Online resource; title from PDF title page (ScienceDirect, viewed February 17, 2017) |
| Subject |
Brain -- Tumors -- Immunotherapy
|
|
Brain Neoplasms -- therapy
|
|
HEALTH & FITNESS -- Diseases -- General.
|
|
MEDICAL -- Clinical Medicine.
|
|
MEDICAL -- Diseases.
|
|
MEDICAL -- Evidence-Based Medicine.
|
|
MEDICAL -- Internal Medicine.
|
| Genre/Form |
Electronic books
|
| Form |
Electronic book
|
| Author |
Sampson, John H., editor
|
| LC no. |
2017285243 |
| ISBN |
9780128026250 |
|
0128026251 |
|
